Identifikation von Exosomen im malignen Pleuraerguss und Aszites gynäkologischer Patientinnen

Zusammenfassung

Fragestellung: Exosomen aus malignem Aszites und Pleuraerguss bieten möglicherweise eine natürliche und neue Quelle der Gewinnung von Exosomen und stellen somit eine Erfolg versprechende Alternative zu tumorzellbasierten Vakzinen dar. Exosomen sind Membranvesikel endosomalen Urprungs mit einer Größe von 60 - 100 nm und einer Dichte von 1,21 g/ml. Die Bildung dieser Membranvesikel durch Tumorzellen konnte in erster Linie in vitro gezeigt werden. Ziel unserer Untersuchung war der Nachweis von Exosomen in vivo im malignen Aszites/Pleuraerguss beim Mammakarzinom und gynäkologischen Tumoren. Methode: Maligner Aszites von gynäkologischen Tumoren und maligner Pleuraerguss beim Mammakarzinom wurde bei acht Patientinnen mittels differenzieller Zentrifugation in fünf Schritten angereichert, gefolgt von einer Dichtezentrifugation mit kontinuierlichem Sukrosegradienten in einer Ultrazentrifuge. Die Charakterisierung und Identifizierung der Exosomen erfolgte mittels SDS-PAGE mit Coomassie-blue-Proteinfärbung, Westernblot-Analyse und Elektronenmikroskopie. Ergebnisse: Exosomen konnten im malignen Pleuraerguss und malignen Aszites gynäkologischer Patientinnen elektronenmikroskopisch nachgewiesen werden. Schlussfolgerung: Wir berichten erstmalig über den Nachweis von Exosomen aus malignem Aszites beim Endometrium- und Pankreaskarzinom. Exosomen bieten möglicherweise eine natürliche und neue pluripotente Quelle für Tumorantigene und eröffnen somit einen neuen Weg der Immunstrategie.

Abstract

Purpose: Tumor derived exosomes isolated from malignant effusions could serve as a new source of tumor-rejection antigens, and thus may lead to a new way to tumor immunotherapy. Exosomes are membrane vesicles of 60 to 100 nm in diameter with a density of 1.21 g/ml, of endocytic origin, and are released in vitro by tumor cell lines in culture supernatants. In vivo and in vitro experiments suggest that exosomes are involved in the transfer of tumor antigens to antigen presenting cells. The aim of this study was the verification of the presence of exosomes in malignant effusions of gynecological cancer patients and their subsequent isolation and characterization. Methods: The isolation of exosomes was performed by ultracentrifugation on sucrose gradients of eight malignant effusions of patients with breast cancer, ovarian cancer, endometrial cancer and pancreatic cancer. The characterization of the exosomes was performed using SDS-PAGE with Coomassie blue staining, Western blot analysis and electron microscopy. Results: In malignant effusions of gynecological patients membrane vesicles with a diameter of 60 - 100 nm could be detected. These isolated membrane vesicles have antigen-presenting molecules (MHC class-I) on their surface. These criteria and the morphological parameters (electron microscopy) indicate the similarities between these vesicles and the exosomes. Conclusion: Exosomes accumulate in malignant effusions of patients with cancer. Importantly, we were able to identify exosomes from malignant effusions of patients with endometrial and pancreatic cancer, which has not been described heretofore. Further investigations using these exosomes have to be performed to analyze the induction of the tumor specifity of T cells when pulsed with dendritic cells.

Exosomen - Immuntherapie - Aszites - Pleuraerguss - Endometriumkarzinom - Pankreaskarzinom

exosomes - malignant effusions - immunotherapy - endometrial cancer - pancreatic cancer

Literatur

• 1 Nestle F O, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R. et al . Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.  Nat Med. 1998;  4 328-332
• 2 Murphy G P, Tjoa B A, Simmons S J, Ragde H, Rogers M, Elgamal A. et al . Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment.  Prostate. 1999;  39 54-59
• 3 Hsu F J, Benike C, Fagnoni F, Liles T M, Czerwinski D, Taidi B. et al . Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells.  Nat Med. 1996;  2 52-58
• 4 Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P. et al . Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.  Nat Med. 2000;  6 332-336
• 5 Vermorken J B, Claessen A M, van Tinteren H, Gall H E, Ezinga R, Meijer S. et al . Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.  Lancet. 1999;  353 345-350
• 6 Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y. et al . Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity.  J Immunol. 2000;  165 1705-1711
• 7 Srivastava P K. Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens.  Methods. 1997;  12 165-171
• 8 Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K, Gregoire M. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines.  Cancer Res. 1999;  59 3329-3332
• 9 Taieb J, Chaput N, Zitvogel L. Dendritic cell-derived exosomes as cell-free peptide-based vaccines.  Crit Rev Immunol. 2005;  25 215-223
• 10 Hsu D H, Paz P, Villaflor G, Rivas A, Mehta-Damani A, Angevin E. et al . Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.  J Immunother. 2003;  26 440-450
• 11 Andre F, Andersen M, Wolfers J, Lozier A, Raposo G, Serra V. et al . Exosomes in cancer immunotherapy: preclinical data.  Adv Exp Med Biol. 2001;  495 349-354
• 12 Andre F, Escudier B, Angevin E, Tursz T, Zitvogel L. Exosomes for cancer immunotherapy.  Ann Oncol. 2004;  15 (Suppl 4) iv141-iv144
• 13 Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D. et al . Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes.  Nat Med. 1998;  4 594-600
• 14 Chaput N, Taieb J, Schartz N, Flament C, Novault S, Andre F. et al . The potential of exosomes in immunotherapy of cancer.  Blood Cells Mol Dis. 2005;  35 111-115
• 15 Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function.  Nat Rev Immunol. 2002;  2 569-579
• 16 Raposo G, Nijman H W, Stoorvogel W, Liejendekker R, Harding C V, Melief C J. et al . B lymphocytes secrete antigen-presenting vesicles.  J Exp Med. 1996;  183 1161-1172
• 17 Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C. et al . Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming.  Nat Med. 2001;  7 297-303
• 18 Andre F, Schartz N E, Movassagh M, Flament C, Pautier P, Morice P. et al . Malignant effusions and immunogenic tumour-derived exosomes.  Lancet. 2002;  360 295-305
• 19 Gromme M, Uytdehaag F G, Janssen H, Calafat J, van Binnendijk R S, Kenter M J. et al . Recycling MHC class I molecules and endosomal peptide loading.  Proc Natl Acad Sci U S A. 1999;  96 10326-10331
• 20 Blom D, Hirsch C, Stern P, Tortorella D, Ploegh H L. A glycosylated type I membrane protein becomes cytosolic when peptide: N-glycanase is compromised.  Embo J. 2004;  23 650-658
• 21 Hsu D LH, Mehta A. et al . A novel acellular approach to cancer immunotherapy: Dexosomes, from bench to bedside.  Proc Am Assoc Cancer Res. 2002;  21 3362
• 22 Andre F, Schartz N E, Chaput N, Flament C, Raposo G, Amigorena S. et al . Tumor-derived exosomes: a new source of tumor rejection antigens.  Vaccine. 2002;  20 (Suppl 4) A28-A31
• 23 Bard M P, Hegmans J P, Hemmes A, Luider T M, Willemsen R, Severijnen L A. et al . Proteomic analysis of exosomes isolated from human malignant pleural effusions.  Am J Respir Cell Mol Biol. 2004;  31 114-121
• 24 Navabi H, Croston D, Hobot J, Clayton A, Zitvogel L, Jasani B. et al . Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial.  Blood Cells Mol Dis. 2005;  35 149-152